The pharmaceutical industry is at the commercial interface between innovation, patients, caregivers and payers. With U.S. elections now behind, the question is out about how the dynamics may shift in favour of one or another stakeholder.
Read the full expert opinion on Drug Discovery World:
Expert opinion on life sciences in a Trump/RFK era